SOLID tumor growth in animals and in man is accompanied by neovascularization. New capillary growth is elicited by a diffusible factor generated by malignant tumor cells. In the absence of neovascularization most tumors might become dormant at a tiny diameter, perhaps 2-3 mm.9 ' 10 Although evidence for these statements is still indirect and fragmentary, it seems appropriate to speculate that the inhibition of angiogenesis, i.e., anti-angiogenesis, may provide a form of cancer therapy worthy of serious exploration. The evidence for such a contention, based on recent findings in our own laboratory and others, will be examined in this report.
Evidence that Tumors Induce New
Blood Vessels Algire I attributed to tumor cells the ability to elicit continuously the growth of new capillary endothelium in vivo. Feigin8 observed vigorous neovascularization in the neighborhood of malignant brain tumors, that seemed to be excited or induced by Submitted for publication June 28, 1971. Jersey, and by gifts from the Given Foundation and the Zaffaroni Foundation.
Reprint requests: Dr. Folkman, Children's Hospital Medical Center, 300 Longwood Avenue, Bos- ton, Massachusetts 02115. the tumor itself. Many other authors, observing tumor growth in the hamster cheek pouch or in the rabbit ear chamber, have described the intense neovascularization around a growing tumor. 3"18, 21 Chaldey4 and Warren22 were the first to hypothesize humoral induction of tumor blood vessels.
Evidence for the Humoral Induction of Tumor Angiogenesis Greenblatt and Shubik 14 demonstrated that vasoproliferative activity was consistently seen in hamster cheek pouch stroma adjacent to tumor implants despite separation of the tumor and its stroma by a millipore filter which prevented the passage of cells. Ehrmann 7 saw the same effect with choriocarcinoma in the hamster cheek pouch. We have demonstrated a similar effect using millipore chambers implanted on the fascial expanse of the dorsal air-sac of the rat. Empty millipore chambers or those containing non-neoplastic cells or fluids, produced no reaction.
More recently we have shown9 that a diffusible factor which is mitogenic for capillary endothelium, can be isolated from animal and human tumor cells. This factor, called tumor-angiogenesis-factor (TAF) is isolated after disrupting tumor cells by nitrogen cavitation. Its important components are ribonucleic acid (25%o) and protein. It is probable that most tumors whether they originate from a cell transformed by virus or carcinogen, or whether they begin as a metastatic implant, must exist early as a small population of cells dependent upon nutrients which diffuse from the extravascular space (Fig. 1) Would such a dormant tumor metastasize? Recent evidence 16 suggests that metastases will diminish when the primary tumor is relatively devascularized. Metastasis from a primary solid tumor may well depend upon the presence of vascularization.
Would nonvascularized, dormant tumors be more susceptible to chemotherapy? Although tiny tumors generally are more vulnerable to chemotherapy, we do not know whether the dormant state resulting from anti-angiogenesis would be maintained by a high rate of cell loss or a decline in mitotic rate. Therefore, one cannot predict what kind of drug might be effective with such tumors. It is conceivable that chemotherapeutic killing of unvascularized tumor implants may actually be the mechanism by which Actinomycin, for example, is capable of preventing the recurrence of Wilms' tumor in the unexcised opposite kidney.
Are the cells in a nonvascularized, tiny tumor implant less hypoxic than those cells living in the avascular core of a large solid vascularized tumor? There may be a great difference between these two situations. It is possible that the cells in the former situation are well oxygenated; necrosis is not seen in these tiny implants. However, cells in the necrotic center of a large tumor may be severely hypoxic because they are surrounded by dense layers of cells competing for available oxygen. 8 If there is such a difference, then the susceptibility of the avascular core of a large tumor to chemotherapy or radiotherapy may be far less than the vulnerability of an unvascularized small tumor implant in which simple diffusion of nutrients and wastes is still sufficient for every cell in the clone.
What would be the susceptibility of an unvascularized, dormant tumor implant to immunologic attack? Again, we can only speculate. It is possible that an unvascu- larized clone of tumor would be vulnerable to attack by immune lymphocytes because these cells can migrate from nearby vessels. It is also possible that circulating antibody would be unable to reach an unvascularized tumor in as high a concentration as it would accumulate in a vascularized tumor because of the diffusion gradient which might exist over such great distances. It is conceivable that unvascularized tumor colonies cannot be enhanced; that they are "out of reach" of humoral antibody and thus are exposed to the full force of mo- Despite these difficulties, it is my belief that anti-angiogenesis is not only possible but plausible. The attempt to achieve it may provide a new understanding of the early phase of solid tumor development.
Summary
Evidence is presented to suggest that neovascularization is mediated through a humoral factor called TAF.
The concept of anti-angiogenesis is proposed to indicate that blockade of TAF might prevent many solid tumors from growing beyond a diameter of 2-3 mm.
Extension of this concept raises new questions for future study. 
